As per the outcomes of a Post hoc analysis issued in ‘Arthritis Research & Therapy’, Ixekizumab (IXE) therapy when used alone or in combination with concomitant MTX therapy portrayed sustained efficacy in active psoriatic arthritis (PsA) patients for up to 1 year of therapy.

This study by Bernard Combe et al. aimed to evaluate the efficacy of IXE in PsA patients for up to 52 weeks. Active PsA patients (455 patients) from the SPIRIT-P1 and SPIRIT-P2 trials were randomized to IXE 80 mg each 4 (IXE Q4W) or 2 weeks (IXE Q2W), following a starting dose of 160 mg. The 52-week assessment included safety and efficacy of these patients who were either given IXE as alone or; IXE plus MTX. Patients attaining ACR20/50/70 responses comprised of the efficacy outcomes.

Out of the total, 177 patients received monotherapy, 230 patients received concomitant MTX use, and 48 patients received other concomitant medicine. One hundred and eighty-three patients received IXE with a constant concomitant MTX dose for 12 months. Similar ACR responses were observed for IXE Q4W and IXE Q2W monotherapy vs. concomitant MTX groups. Details of ACR20/50/70 responses in IXE Q4W monotherapy vs. concomitant MTX groups has been shown in table 1:

It can thus be concluded that the study results reveal a consistent safety profile and clinically noteworthy efficacy.